Leica Microsystems Inc.
$942.6K 487 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
NS Pharma, Inc.
NS Pharma, Inc. reported $942,067.28 across General Payments, Research, and Ownership to 369 physicians and teaching hospitals across 546 transactions.
- $942.1K
- All-tracks total
- 546
- Transactions
- 369
- Recipients
- −$10.4K
- General Payments vs PY2023
NS Pharma, Inc. reported $942,067.28 across all CMS Open Payments tracks (General + Research + Ownership) to 369 physicians and teaching hospitals in Program Year 2024 - ranking #633 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $103,068.73, averaging $2.6K per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer ns-pharma-inc NS Pharma, Inc.
$942.1K · #633/1,925 · 0.0% industry · PY2024
- TOT $942.1K
- RANK #633
- SHARE 0.0%
- TXN 546
- RCP 369
- CAT 5
- GEN $103.1K
- ΔGEN −$10.4K
- TOP1 36.3%
- PY 2024
Volume peers
Nearest volume peer: Leica Microsystems Inc. ($942.6K)
NS Pharma, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
NS Pharma, Inc.'s CMS-reported General Payments decreased by $10.4K (−9.2%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: NS PHARMA, INC.PY2023: NS PHARMA, INC.PY2024: NS Pharma, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $113,462.93
- PY2024
- $103,068.73
What the Data Shows for NS Pharma, Inc.
Rank #633 of 1,925 companies in CMS Open Payments for 2024 belongs to NS Pharma, Inc., which reported $942,067.28 across 546 transactions to 369 recipients - a comparatively small 0.0% slice of all industry payments reported nationwide for the year. Averages work out to $1.7K per transaction and $2.6K per recipient.
The 5-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Honoraria" at $39.1K, accounting for 37.9% of this company's General Payments and 26 transactions.
General Payment Breakdown by Type
"Honoraria" leads NS Pharma, Inc.'s 5-category general-payment breakdown at $39.1K, 37.9% of the reported total.
NS Pharma, Inc. reports 5 general-payment categories - the top three are Honoraria (37.9%), Consulting Fee (18.9%), and Travel and Lodging (17.7%). The remaining 2 categories make up 25.5% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How NS Pharma, Inc. divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Honoraria | $39.1K | 26 | 37.9% |
| Consulting Fee | $19.4K | 3 | 18.9% |
| Travel and Lodging | $18.3K | 34 | 17.7% |
| Food and Beverage | $13.8K | 301 | 13.4% |
| Grant | $12.5K | 5 | 12.1% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $76,521.60 (74.2%) of $103,068.73 in this company's General Payments records across 225 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for NS Pharma, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Kan Hor
$37,402.44 across 48 reported transactions
- 2
Peter Merkel
$17,187.50 across 2 reported transactions
- 3
John Jefferies
$8,437.88 across 11 reported transactions
- 4
Mathula Thangarajh
$7,587.51 across 12 reported transactions
- 5
Michelle Figueroa
$5,906.27 across 8 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as NS Pharma, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about NS Pharma, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with NS Pharma, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Vascular Technology, Inc.
$943.2K 50 recipients
Compare payment profiles
OrganOx Ltd
$944.6K 100 recipients
Compare payment profiles
Heron Therapeutics, Inc.
$945.0K 4,695 recipients
Compare payment profiles
Consortium of Independent Immunology Clinics, LLC
$938.8K 91 recipients
Compare payment profiles
Carl Zeiss Meditec, Inc.
$938.6K 737 recipients
Compare payment profiles
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.